Search results

Filters

  • Journals
  • Authors
  • Keywords
  • Date
  • Type

Search results

Number of results: 1
items per page: 25 50 75
Sort by:
Download PDF Download RIS Download Bibtex

Abstract

Abnormal DNA methylation is involved in the initiation and progression of lymphoid tumors. Hence, DNA demethylating agents are promising candidate drugs for chemotherapy against these tumors. The salicylic acid derived anti-inflammatory agent, olsalazine, reportedly suppresses DNA methyltransferase in human cells and has the potential to be clinically applied as a DNA demethylating agent. In this study, we investigated the effects of olsalazine on cell proliferation and DNA methylation using canine lymphoid tumor cell lines (CLBL-1, GL-1, and UL-1). Treatment with olsalazine led to significant cell growth inhibition and increased the apoptotic rate in all three cell lines. Treatment with olsalazine reduced the total amount of 5-methylcytosine in genomic DNA, as assessed by enzyme-linked immunosorbent assay. Genome-wide analysis of DNA methylation revealed that 1,801 to 5,626 CpG sites showed decreased DNA methylation levels in three cell lines, including the promoter regions of ADAM23, FES, and CREB3L1 genes. The outcomes of the present study demonstrate that a DNA demethylating agent olsalazine, inhibits cell proliferation and DNA methylation in canine lymphoid tumor cells, suggesting that it can be a candidate drug for the treatment of lymphoid tumors in dogs.
Go to article

Bibliography


Bennett AL, Williams LE, Ferguson MW, Hauck ML, Suter SE, Lanier CB, Hess PR (2017) Canine acute leukaemia: 50 cases (1989-2014). Vet Comp Oncol 15: 1101-1114.

Brown WA, Farmer KC, Skinner SA, Malcontenti-Wilson C, Misajon A, O’Brien PE (2000) 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 45: 1578-1584.

Campbell DE, Berglindh T (1988) Pharmacology of olsalazine. Scand J Gastroenterol Suppl 148: 7-12.

Choi JS, Kim KH, Jeon YK, Kim SH, Jang SG, Ku JL, Park JG (2009) Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues. Int J Cancer 124: 1258-1262.

Eden A, Gaudet F, Waghmare A, Jaenisch R (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455.

Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, Fernandez H, Tallman MS, Greally JM, Carraway H, Licht JD (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114: 3448-3458.

Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S, Gil L, Girón CG, Gordon L, Hourlier T, Hunt S, Johnson N, Juettemann T, Kähäri AK, Keenan S, Kulesha E, Martin FJ, Maurel T, McLaren WM, Murphy DN, Nag R, Overduin B, Pignatelli M, Pritchard B, Pritchard E, Riat HS, Ruffier M, Sheppard D, Taylor K, Thormann A, Trevanion SJ, Vullo A, Wilder SP, Wilson M, Zadissa A, Aken BL, Birney E, Cunningham F, Harrow J, Herrero J, Hubbard TJ, Kinsella R, Muffato M, Parker A, Spudich G, Yates A, Zerbino DR, Searle SM (2014) Ensembl 2014. Nucleic Acids Res 42: D749-755.

Fujiwara-Igarashi A, Goto-Koshino Y, Mochizuki H, Sato M, Fujino Y, Ohno K, Tsujimoto H (2014) Inhibition of p16 tumor suppressor gene expression via promoter hypermethylation in canine lymphoid tumor cells. Res Vet Sci 97: 60-63.

Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196: 261-282.

Grovdal M, Karimi M, Tobiasson M, Reinius L, Jansson M, Ekwall K, Ungerstedt J, Kere J, Greco D, Hellström-Lindberg E (2014) Aza-citidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acety-lation. Leukemia 28: 411-413.

Hahn NM, Bonney PL, Dhawan D, Jones DR, Balch C, Guo Z, Hartman-Frey C, Fang F, Parker HG, Kwon EM, Ostrander EA, Nephew KP, Knapp DW (2012) Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. J Urol 187: 302-309.

Harman RM, Curtis TM, Argyle DJ, Coonrod SA, Van de Walle GR (2016) A Comparative Study on the In Vitro Effects of the DNA Me-thyltransferase Inhibitor 5-Azacytidine (5-AzaC) in Breast/Mammary Cancer of Different Mammalian Species. J Mammary Gland Biol Neo-plasia 21: 51-66.

Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM (1991) Silencing of the VHL tu-mor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704.

Hogg SJ, Beavis PA, Dawson MA, Johnstone RW (2020) Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov 19: 776-800.

Hosoya K, Kisseberth WC, Lord LK, Alvarez FJ, Lara-Garcia A, Kosarek CE, London CA, Couto CG (2007) Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma. J Vet Intern Med 21: 1355-1363.

Ishizaki T, Yamazaki J, Meagawa S, Yokoyama N, Aoshima K, Takiguchi M, Kimura T (2020) Long interspersed nucleotide element-1 hy-pomethylation in canine malignant mucosal melanoma. Vet Comp Oncol 18: 854-860.

Malewska K, Rychlik A, Nieradka R, Kander M (2011) Treatment of inflammatory bowel disease (IBD) in dogs and cats. Pol J Vet Sci 14: 165-171.

Mehdipour P, Murphy T, De Carvalho DD (2020) The role of DNA-demethylating agents in cancer therapy. Pharmacol Ther 205: 107416.

Mendez-Lucio O, Tran J, Medina-Franco JL, Meurice N, Muller M (2014) Toward drug repurposing in epigenetics: olsalazine as a hypo-methylating compound active in a cellular context. Chem Med Chem 9: 560-565.

Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692.

Mohammad HP, Barbash O, Creasy CL (2019) Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med 25: 403-418.

Moore AS (2016) Treatment of T cell lymphoma in dogs. Vet Rec 179: 277.

Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK (2020) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 8: CD000544.

Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K; Cancer Genome Atlas Research Network (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.

Ohta H, Yamazaki J, Jelinek J, Ishizaki T, Kagawa Y, Yokoyama N, Nagata N, Sasaki N, Takiguchi M (2020) Genome-wide DNA methyla-tion analysis in canine gastrointestinal lymphoma. J Vet Med Sci 82: 632-638.

Pawlak A, Rapak A, Zbyryt I, Obminska-Mrukowicz B (2014) The effect of common antineoplastic agents on induction of apoptosis in ca-nine lymphoma and leukemia cell lines. In Vivo 28: 843-850.

Pera B, Tang T, Marullo R, Yang SN, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J, Cerchietti L, Martin P (2016) Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clin Epigenetics 8: 79.

Ribeiro ML, Reyes-Garau D, Armengol M, Fernandez-Serrano M, Roue G (2019) Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. Front Genet 10: 986.

Rose M, Schubert C, Dierichs L, Gaisa NT, Heer M, Heidenreich A, Knüchel R, Dahl E (2014) OASIS/ /CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro. Epigenetics 9: 1626-1640.

Ryde EM, Ahnfelt NO (1988) The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food. Eur J Clin Pharmacol 34: 481-488.

Shaffer JM, Smithgall TE (2009) Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer. Genes Chromosomes Cancer 48: 272-284.

Takeshima H, Yoda Y, Wakabayashi M, Hattori N, Yamashita S, Ushijima T. (2020) Low-dose DNA demethylating therapy induces repro-gramming of diverse cancer-related pathways at the single-cell level. Clin Epigenetics 12: 142.

Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, Karimi M, Krjutskov K, Einarsdottir E, Grövdal M, Jansson M, Ben Azenkoud A, Corddedu L, Lehmann S, Ekwall K, Kere J, Hellström-Lindberg E, Ungerstedt J (2017) Comprehensive map-ping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease. Oncotarget 8: 28812-28825.

Tomar T, de Jong S, Alkema NG, Hoekman RL, Meersma GJ, Klip HG, van der Zee AG, Wisman GB (2016) Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. Genome Med 8: 107.

Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H (2014) Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines. Vet J 201: 83-90.

Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H (2014) Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients. Vet J 199: 103-109.

Valerius KD, Ogilvie GK, Mallinckrodt CH, Getzy DM (1997) Doxorubicin alone or in combination with asparaginase, followed by cyclo-phosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 210: 512-516.

Yamazaki J, Jelinek J, Hisamoto S, Tsukamoto A, Inaba M (2018) Dynamic changes in DNA methylation patterns in canine lymphoma cell lines demonstrated by genome-wide quantitative DNA methylation analysis. Vet J 231: 48-54.
Go to article

Authors and Affiliations

S. Itoh
1 2
J. Yamazaki
3 4
M. Iwahana
2
A. Tsukamoto
2

  1. Laboratory of Biology, Azabu University, School of Veterinary Medicine, 1-17-71 Fuchinobe, Chuou-ku, Sagamihara, Kanagawa 252-5201, Japan
  2. Laboratory of Laboratory Animal Science, Azabu University, School of Veterinary Medicine, 1-17-71 Fuchinobe, Chuou-ku, Sagamihara, Kanagawa 252-5201, Japan
  3. Veterinary Teaching Hospital, Graduate School of Veterinary Medicine, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo, Hokkaido, 060-0808, Japan
  4. One Health Research Center, Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo, Hokkaido, 060-0808, Japan

This page uses 'cookies'. Learn more